| Budget Amount *help |
¥22,880,000 (Direct Cost: ¥17,600,000、Indirect Cost: ¥5,280,000)
Fiscal Year 2017: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥14,170,000 (Direct Cost: ¥10,900,000、Indirect Cost: ¥3,270,000)
|
|---|
| Outline of Final Research Achievements |
The patients with kidney disease are increasing in both companion animals and human. Early diagnosis is a crucial therapeutic strategy for non-regenerative kidney. In this study, we tried to find the biomarker candidates from urinary exosome-derived microRNA to develop the non-invasive “Liquid Biopsy”. In the comprehensive expression analysis and pathological analysis of animals, we identified miR-26a as a candidate for renal glomerular injury marker. Further, several animal species commonly expressed miR-26a in their glomeruli, indicating a possibility of animal species-crossing biomarker. Further, for the application of miRNA to clinical area, we need to clarify further miRNA marker candidates, their correlations with renal function, their dynamics at early disease stage, and their pathological relations with tubulointerstitial lesions.
|
